Altered vascular phenotype in autism: correlation with oxidative stress
A total of 174,584 patients on semaglutide (mean age 58.3 years) and an equal number on nonGLP1 RA medications (mean age 58.2 years) were analyzed
In the SUSTAIN 3, 7, and 10 trials, semaglutide was found to be superior to other GLP-1RAs at lowering glycated hemoglobin and body weight
It is whether the benefit, tolerability, timing, and access picture will hold up once the headlines cool off
It does this in tissues, including muscles and bones
Appetite and Fullness Some patients feel stronger appetite suppression within the first few weeks, while others notice a more gradual effect as doses increase